These findings help to explain the disparity between the effects of pharmacologic p38 inhibitors and cardiomyocyte-specific KO/inhibition models for inhibiting cardiac hypertrophy in vivo. This evidence concerns the gene MAPK14 and cardiac hypertrophy.